To the best of our knowledge, this is the largest real-world study to evaluate the benefits of SGLT2i and GLP1-ra on diabetic retinopathy and DMO in individuals with type 2 diabetes receiving insulin. This evidence concerns the gene INS and diabetic retinopathy.